公开(公告)号：US20160318915A1

公开(公告)日：2016-11-03

申请号：US15209731

申请日：2016-07-13

申请人： Thomas Raymond CAFERRO ,  Zhuoliang CHEN ,  Young Shin CHO ,  Abran Q. COSTALES ,  Julian Roy LEVELL ,  Gang LIU ,  James R. MANNING ,  Martin SENDZIK ,  Cynthia SHAFER ,  Michael David SHULTZ ,  James Clifford SUTTON ,  Yaping WANG ,  Qian ZHAO

发明人： Thomas Raymond CAFERRO ,  Zhuoliang CHEN ,  Young Shin CHO ,  Abran Q. COSTALES ,  Julian Roy LEVELL ,  Gang LIU ,  James R. MANNING ,  Martin SENDZIK ,  Cynthia SHAFER ,  Michael David SHULTZ ,  James Clifford SUTTON ,  Yaping WANG ,  Qian ZHAO

IPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14

CPC分类号： C07D413/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D417/14

摘要： The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

摘要翻译： 或其药学上可接受的盐，其中R1，R2a，R2b和R3-R7为本文。 本发明还涉及含有式（I）化合物的组合物以及这些化合物在抑制具有新形态活性的突变体IDH蛋白质中的用途。 本发明还涉及式（I）化合物在治疗与这种突变体IDH蛋白相关的疾病或病症中的用途，包括但不限于细胞增殖病症如癌症。

公开(公告)号：US20140275083A1

公开(公告)日：2014-09-18

申请号：US14208015

申请日：2014-03-13

申请人： Thomas Raymond CAFERRO ,  Zhuoliang CHEN ,  Young Shin CHO ,  Abran Q. COSTALES ,  Julian Roy LEVELL ,  Gang LIU ,  James R. MANNING ,  Martin SENDZIK ,  Cynthia SHAFER ,  Michael David SHULTZ ,  James SUTTON ,  Yaping WANG ,  Qian ZHAO

发明人： Thomas Raymond CAFERRO ,  Zhuoliang CHEN ,  Young Shin CHO ,  Abran Q. COSTALES ,  Julian Roy LEVELL ,  Gang LIU ,  James R. MANNING ,  Martin SENDZIK ,  Cynthia SHAFER ,  Michael David SHULTZ ,  James SUTTON ,  Yaping WANG ,  Qian ZHAO

IPC分类号： C07D413/04 ,  A61K31/5377 ,  C07D417/14 ,  C07D413/14 ,  A61K31/506

CPC分类号： C07D413/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D417/14

摘要： The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

摘要翻译： 本发明涉及式（I）：或其药学上可接受的盐，其中R1，R2a，R2b和R3-R7为本文。 本发明还涉及含有式（I）化合物的组合物以及这些化合物在抑制具有新形态活性的突变体IDH蛋白质中的用途。 本发明还涉及式（I）化合物在治疗与这种突变体IDH蛋白相关的疾病或病症中的用途，包括但不限于细胞增殖病症如癌症。

公开(公告)号：US20140249135A1

公开(公告)日：2014-09-04

申请号：US14273595

申请日：2014-05-09

申请人： Matthew Burger ,  Mika Lindvall ,  Wooseok Han ,  Jiong Lan ,  Gisele Nishiguchi ,  Cynthia Shafer ,  Cornelia Bellamacina ,  Kay Huh ,  Gordana Atallah ,  Christopher McBride ,  William Antonios-McCrea, JR. ,  Tatiana Zavorotinskaya ,  Annette Walter ,  Pablo Dominguez Garcia

发明人： Matthew Burger ,  Mika Lindvall ,  Wooseok Han ,  Jiong Lan ,  Gisele Nishiguchi ,  Cynthia Shafer ,  Cornelia Bellamacina ,  Kay Huh ,  Gordana Atallah ,  Christopher McBride ,  William Antonios-McCrea, JR. ,  Tatiana Zavorotinskaya ,  Annette Walter ,  Pablo Dominguez Garcia

IPC分类号： C07D401/12 ,  A61K31/55 ,  A61K31/497 ,  A61K31/4545 ,  A61K31/444 ,  C07D491/113 ,  C07D403/12 ,  A61K31/506 ,  C07D241/28 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D497/04 ,  C07D403/14 ,  A61K31/553

CPC分类号： C07D401/12 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/506 ,  A61K31/55 ,  A61K31/553 ,  C07D241/24 ,  C07D241/28 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D491/113 ,  C07D497/04

摘要： New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

摘要翻译： 提供了在人或动物受试者中抑制与肿瘤发生相关的激酶活性的新化合物，组合物和方法。 在某些实施方案中，化合物和组合物有效抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用，用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症，例如癌症。

公开(公告)号：US20090170904A1

公开(公告)日：2009-07-02

申请号：US12315779

申请日：2008-12-05

申请人： Mina E. Aikawa ,  Payman Amiri ,  Jeffrey H. Dove ,  Barry Haskell Levine ,  Christopher McBride ,  Teresa E. Pick ,  Daniel J. Poon ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia Shafer ,  Darrin Stuart ,  Sharadha Subramanian

发明人： Mina E. Aikawa ,  Payman Amiri ,  Jeffrey H. Dove ,  Barry Haskell Levine ,  Christopher McBride ,  Teresa E. Pick ,  Daniel J. Poon ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia Shafer ,  Darrin Stuart ,  Sharadha Subramanian

IPC分类号： A61K31/4439 ,  A61P35/00

CPC分类号： C07D401/14 ,  Y02P20/55

摘要： New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

公开(公告)号：US20070161680A1

公开(公告)日：2007-07-12

申请号：US11513959

申请日：2006-08-30

申请人： Mina Alkawa ,  Payman Amiri ,  Jeffrey Dove ,  Barry Levine ,  Christopher McBride ,  Teresa Pick ,  Daniel Poon ,  Savithri Ramurthy ,  Paul Renhowe ,  Cynthia Shafer ,  Darrin Stuart ,  Sharadha Subramanian

发明人： Mina Alkawa ,  Payman Amiri ,  Jeffrey Dove ,  Barry Levine ,  Christopher McBride ,  Teresa Pick ,  Daniel Poon ,  Savithri Ramurthy ,  Paul Renhowe ,  Cynthia Shafer ,  Darrin Stuart ,  Sharadha Subramanian

IPC分类号： A61K31/4439 ,  C07D403/14

CPC分类号： C07D401/14 ,  Y02P20/55

摘要： New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

摘要翻译： 提供了新的取代的苯并咪唑化合物，组合物和抑制与人或动物受试者的肿瘤发生相关的激酶活性的方法。 在某些实施方案中，化合物和组合物有效地抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用，用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症，例如癌症。

公开(公告)号：US20070032528A1

公开(公告)日：2007-02-08

申请号：US11546814

申请日：2006-10-11

申请人： Paul Renhowe ,  Timothy Machajewski ,  Cynthia Shafer ,  Mary Ellen Hammond ,  Sabina Pecchi

发明人： Paul Renhowe ,  Timothy Machajewski ,  Cynthia Shafer ,  Mary Ellen Hammond ,  Sabina Pecchi

IPC分类号： A61K31/4439 ,  C07D417/04 ,  C07D413/04 ,  C07D403/04

CPC分类号： C07D471/04 ,  C07D495/04

摘要： Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

摘要翻译： 提供具有结构式I的有机化合物，其中变量具有本文所述的值，并且R 1和R 2连接在一起以形成6元取代或未取代的环，其包括在 至少一个O，N或S原子，Z是O，S，NH或NR基团。 药物制剂包括有机化合物或其药学上可接受的盐和药学上可接受的载体。

公开(公告)号：US07138409B2

公开(公告)日：2006-11-21

申请号：US10823995

申请日：2004-04-14

申请人： Paul A. Renhowe ,  Timothy Machajewski ,  Cynthia Shafer ,  Mary Ellen Wernette Hammond ,  Sabina Pecchi

发明人： Paul A. Renhowe ,  Timothy Machajewski ,  Cynthia Shafer ,  Mary Ellen Wernette Hammond ,  Sabina Pecchi

IPC分类号： C07D413/14 ,  C07D471/02 ,  A61K31/436 ,  A61K31/4375

CPC分类号： C07D471/04 ,  C07D495/04

摘要： Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

摘要翻译： 提供具有结构式I的有机化合物，其中变量具有本文所述的值，并且R 1和R 2连接在一起以形成6元取代或未取代的环，其包括在 至少一个O，N或S原子，Z是O，S，NH或NR基团。 药物制剂包括有机化合物或其药学上可接受的盐和药学上可接受的载体。

公开(公告)号：US20050192287A1

公开(公告)日：2005-09-01

申请号：US10967089

申请日：2004-10-15

申请人： Abran Costales ,  Teresa Hansen ,  Barry Levine ,  Christopher McBride ,  Daniel Poon ,  Savithri Ramurthy ,  Paul Renhowe ,  Cynthia Shafer ,  Sharadha Subramanian ,  Joelle Verhagen

发明人： Abran Costales ,  Teresa Hansen ,  Barry Levine ,  Christopher McBride ,  Daniel Poon ,  Savithri Ramurthy ,  Paul Renhowe ,  Cynthia Shafer ,  Sharadha Subramanian ,  Joelle Verhagen

IPC分类号： A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/506 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12

CPC分类号： C07D401/12 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  C04B35/632 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

摘要： New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

摘要翻译： 提供了新的取代的苯唑化合物，抑制人或动物受试者中的Raf激酶活性的组合物和方法。 新化合物组合物可以单独使用或与至少一种另外的药物组合使用，用于治疗Raf激酶介导的病症，例如癌症。

公开(公告)号：US20050054672A1

公开(公告)日：2005-03-10

申请号：US10886950

申请日：2004-07-08

申请人： Paul Renhowe ,  Sabina Pecchi ,  Timothy Machajewski ,  Cynthia Shafer ,  Clarke Taylor ,  William McCrea ,  Christopher McBride ,  Elisa Jazan

发明人： Paul Renhowe ,  Sabina Pecchi ,  Timothy Machajewski ,  Cynthia Shafer ,  Clarke Taylor ,  William McCrea ,  Christopher McBride ,  Elisa Jazan

IPC分类号： C07D243/08 ,  A61K31/19 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61P35/00 ,  A61P43/00 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D453/02 ,  C07D471/04 ,  C07D487/08 ,  C07D519/00 ,  C07D43/04

CPC分类号： C07D409/04 ,  A61K31/19 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/513 ,  C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D453/02 ,  C07D471/04 ,  A61K2300/00

摘要： Organic compounds having the formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

摘要翻译： 提供具有式I的有机化合物，其中变量具有本文所述的值。 药物制剂包括有机化合物或其药学上可接受的盐和药学上可接受的载体，并且可以通过将有机化合物的有机化合物或药学上可接受的盐与载体和水混合来制备。 治疗患者的方法包括向有需要的患者施用本发明的药物制剂。

公开(公告)号：US09434719B2

公开(公告)日：2016-09-06

申请号：US14408418

申请日：2014-03-12

申请人： Thomas Raymond Caferro ,  Zhuoliang Chen ,  Young Shin Cho ,  Abran Q. Costales ,  Julian Roy Levell ,  Gang Liu ,  James R. Manning ,  Martin Sendzik ,  Cynthia Shafer ,  Michael David Shultz ,  James Sutton ,  Yaping Wang ,  Qian Zhao

发明人： Thomas Raymond Caferro ,  Zhuoliang Chen ,  Young Shin Cho ,  Abran Q. Costales ,  Julian Roy Levell ,  Gang Liu ,  James R. Manning ,  Martin Sendzik ,  Cynthia Shafer ,  Michael David Shultz ,  James Sutton ,  Yaping Wang ,  Qian Zhao

IPC分类号： C07D413/04 ,  A61K31/506 ,  C07D413/14 ,  C07D417/14 ,  A61K31/5377

CPC分类号： C07D413/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D417/14

摘要： The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.